Table 1. Baseline characteristics of the cohort, stratified by Pseudo-Myxoma Peritonei Consortium Score, n = 1,847

Characteristic	Total cohort		PMP Score 0–2		PMP Score 3–5		PMP Score 6–8		Standardized mean difference		Kaplan–Meier 5-year overall survival, % (95% CI)		Kaplan–Meier 5-year disease-free survival, % (95% CI)	
	n	%	n	%	n	%	n	%						
Age, years	58	49–67	56	48–65	60	51–68	63	54–71	0.18	0.09–0.27	71.4	68.2–74.6	64.0	60.7–67.3
Female sex	1,109	60.0	612	58.4	318	61.2	179	63.0	0.07	0.02–0.12	73.1	70.0–76.2	66.5	63.4–69.6
Male sex	738	40.0	436	41.6	201	38.8	101	37.0			67.8	63.9–71.7	60.2	56.4–64.0
Appendiceal primary	1,402	75.9	812	77.5	391	75.2	199	70.0	0.11	0.04–0.18	74.6	71.7–77.5	67.2	64.3–70.1
Colorectal primary	445	24.1	236	22.5	128	24.8	81	28.5			65.4	60.2–70.6	58.9	53.7–64.1
Grade 1	312	16.9	198	18.9	71	13.7	43	15.1	0.21	0.13–0.29	82.6	78.9–86.3	74.1	70.4–77.8
Grade 2	1,031	55.8	588	56.1	287	55.2	156	54.9			71.2	68.4–74.0	63.8	60.9–66.7
Grade 3	504	27.3	262	25.0	162	31.1	85	29.9			58.3	53.6–63.0	51.2	46.5–55.9
Cytoreduction: complete (CC-0)	1,118	60.5	672	64.1	287	55.2	159	55.9	0.14	0.06–0.22	78.9	76.2–81.6	71.4	68.7–74.1
Cytoreduction: CC-1	729	39.5	376	35.9	232	44.6	121	42.6			62.1	57.8–66.4	55.7	51.4–60.0
Peritonectomy performed	612	33.1	318	30.3	198	38.1	96	33.8	0.09	−0.02–0.20	76.4	72.9–79.9	69.0	65.4–72.6
HIPEC administered	487	26.4	251	23.9	171	32.9	65	22.9	0.22	0.14–0.30	79.2	75.6–82.8	70.5	66.8–74.2
Mucinous histology	1,184	64.1	690	65.8	332	63.8	162	57.0	0.13	0.05–0.21	73.8	70.9–76.7	66.2	63.3–69.1
Signet ring cell histology	118	6.4	61	5.8	34	6.5	23	8.1	0.06	−0.04–0.16	64.2	56.7–71.7	58.0	50.5–65.5

Values are median (IQR) or n (%). Standardized mean difference > 0.10 indicates a meaningful difference between groups. Survival estimates are Kaplan–Meier estimates with 95% confidence intervals. Cytoreduction and HIPEC data were missing for 14 patients (0.8%) and 9 patients (0.5%), respectively.

(2) Intraperitoneal chemotherapy with cisplatin and mitomycin C was administered to 487 patients (26.4%) with a median intraperitoneal dwell time of 90 minutes (IQR, 75–90) and a median total dose of 340 mg/m² (IQR, 320–360). Grade 3 or 4 hematologic toxicity occurred in 112 patients (23.0%), with no treatment-related mortality observed within 30 days. Propensity score matching yielded 312 pairs with standardized mean differences < 0.10 for all covariates.

(3) Mucinous histology was associated with worse 5-year disease-free survival (64.2% versus 71.8%; hazard ratio, 1.41; 95% confidence interval, 1.12–1.78; adjusted hazard ratio, 1.29; 95% confidence interval, 1.02–1.64; interaction with HIPEC, p = 0.08), suggesting that the benefit of cytoreduction may be attenuated in this histologic subtype. Signet ring cell histology was associated with the lowest 5-year overall survival (58.0%) and the most frequent peritoneal recurrence (41.2%). Sensitivity analyses excluding patients with missing HIPEC data yielded hazard ratios differing by less than 0.05.

Table T20-0009
Baseline Distribution of Income and Federal Taxes
by Expanded Cash Income Percentile, 2012 [1]

Expanded Cash Income Percentile [2,3]	Tax Units: Number (thousands)	Tax Units: Percent of Total	Average Income (Dollars)	Average Federal Tax Burden (Dollars)	Average After-Tax Income [4] (Dollars)	Average Federal Tax Rate [5]	Share of Pre-Tax Income: Percent of Total	Share of Post-Tax Income: Percent of Total	Share of Federal Taxes: Percent of Total
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]									
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Number of AMT Taxpayers (millions): 4.5

(2) Includes both filing and non-filing units but excludes those that are dependents of other tax units. Tax units with negative adjusted gross income are excluded from their respective income class but are included in the totals. For a description of expanded cash income, see
http://www.taxpolicycenter.org/TaxModel/income.cfm
(3) The income percentile classes used in this table are based on the income distribution for the entire population and contain an equal number of people, not tax units. The breaks are (in 2009 dollars): 20% $24,200; 40% $47,300; 60% $83,100; 80% $149,100; 90% $218,800; 95% $310,800; 99% $733,000; 99.9% $3,259,800

(4) After-tax income is expanded cash income less: individual income tax net of refundable credits; corporate income tax; payroll taxes (Social Security and Medicare); estate tax; and excise taxes.
(5) Average federal tax (includes individual and corporate income tax, payroll taxes for Social Security and Medicare, the estate tax, and excise taxes) as a percentage of average expanded cash income

Table 1. (2026)

Prevalence Rate Ratios of Immune-mediated Diseases by Sex and Age in Three Nationwide Cohorts (Sweden, 1964–2017)

Immune-mediated disease	Sex Ratio		Average Age (Years)	Average Age of Onset (Years)	Average Age Gap (Years)	Average Age Gap (Years)	Mean Lifetime Prevalence Rate (Per 100,000)	Standard Deviation (Per 100,000)	Coefficient of Variation (Per 100,000)
	Prevalence Rate Ratio	Incidence Rate Ratio							
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Table 1. [illegible]
Prevalence Rate Ratios of Dementia and Mortality with Pneumococcal Vaccination, Medicare Beneficiaries, Ontario, Canada, 1996–2017

Vaccination Status	Year Vaccinated		Incidence Rate Ratio (IRR)	Hazard Ratio (HR)	Hazard Ratio (HR)	Hazard Ratio (HR)	Hazard Ratio (HR)	Hazard Ratio (HR)	Hazard Ratio (HR)	Hazard Ratio (HR)
	Dementia	Mortality								
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Table 1. Mediation Effects of Economic Leadership on Financial Performance by Digital Market Orientation in Kandahar, 2026 (n = 1,000)

Indirect effect	Total effect	Direct effect	95% CI lower	95% CI upper	Proportion mediated (%)	Sobel z	Bootstrap SE	Bootstrap 95% CI lower	Bootstrap 95% CI upper	Bootstrap bias-corrected 95% CI lower	Bootstrap bias-corrected 95% CI upper
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Note. [illegible] Bootstrap SE = bootstrap standard error; CI = confidence interval; [illegible]

Received: [illegible] Revised: [illegible] Accepted: [illegible] Published online: [illegible]
Corresponding author: [illegible] Email: [illegible]
Cite this article: [illegible]

© [illegible] Kandahar Office of Strategy and Data Analytics. Distributed under the Creative Commons Attribution 4.0 International License. [illegible]

Table 7.0.0.1.0.0.0.1
Dynamics Mind Medium Lithium Lithium Lithium Mind Female
Big Regulation Water Consumer Economy Lithium, 1993–2017

Consumption Economy Consumer	Year Water		Average Lithium Lithium	Average Mind Lithium	Average Water Lithium	Average Mind Year Water	Mass Lithium Mass Lithium	Economy Economy Lithium	Female Female Lithium
	Consumption	Consumption					Consumption	Consumption	Consumption
Lithium	0.0–0.1	0.0–0.1	0.0–0.1	0.0–0.1	0.0–0.1	0.0–0.1	0.0–0.1	0.0–0.1	0.0–0.1
Water	0.1–0.2	0.1–0.2	0.1–0.2	0.1–0.2	0.1–0.2	0.1–0.2	0.1–0.2	0.1–0.2	0.1–0.2
Mind	0.2–0.3	0.2–0.3	0.2–0.3	0.2–0.3	0.2–0.3	0.2–0.3	0.2–0.3	0.2–0.3	0.2–0.3
Lithium	0.3–0.4	0.3–0.4	0.3–0.4	0.3–0.4	0.3–0.4	0.3–0.4	0.3–0.4	0.3–0.4	0.3–0.4
Water	0.4–0.5	0.4–0.5	0.4–0.5	0.4–0.5	0.4–0.5	0.4–0.5	0.4–0.5	0.4–0.5	0.4–0.5
Mind	0.5–0.6	0.5–0.6	0.5–0.6	0.5–0.6	0.5–0.6	0.5–0.6	0.5–0.6	0.5–0.6	0.5–0.6
Lithium	0.6–0.7	0.6–0.7	0.6–0.7	0.6–0.7	0.6–0.7	0.6–0.7	0.6–0.7	0.6–0.7	0.6–0.7
Water	0.7–0.8	0.7–0.8	0.7–0.8	0.7–0.8	0.7–0.8	0.7–0.8	0.7–0.8	0.7–0.8	0.7–0.8
Mind	0.8–0.9	0.8–0.9	0.8–0.9	0.8–0.9	0.8–0.9	0.8–0.9	0.8–0.9	0.8–0.9	0.8–0.9
Lithium	0.9–1.0	0.9–1.0	0.9–1.0	0.9–1.0	0.9–1.0	0.9–1.0	0.9–1.0	0.9–1.0	0.9–1.0

Source: Lithium Water Consumer Mind Lithium.

[1] Economic Mind Water Lithium Water Water Water

Table 7.0.0.1.0.0.0.1

Acquaintance Mediation Conversation Landmark Pound

Big Regulation Ecosystem Conversation Lawsuit, 1993–1

Conversation Ecosystem Conversation	Year Ecosystem		Average Lawsuit Collaborate	Average Lawsuit Collaborate	Average Lawsuit Collaborate	Average Lawsuit Year Ecosystem	Mediation Conversation Ecosystem	Ecosystem Conversation Lawsuit	Ecosystem Conversation Lawsuit
	Conversation Lawsuit	Conversation Lawsuit	Lawsuit	Lawsuit	Lawsuit	Lawsuit	Lawsuit	Lawsuit	Lawsuit
Ecosystem Lawsuit Lawsuit	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)
Lawsuit Lawsuit Lawsuit	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)
Lawsuit Lawsuit	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)
Lawsuit	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)	0.0000 (0.0000)
Lawsuit

Table 1. Mediation Effects of Innovation and Risk Taking on the Relationship between Entrepreneurial Orientation and Firm Performance

Independent Variable (Entrepreneurial Orientation)	Dependent Variable (Firm Performance)		Mediator (Innovation)		Mediator (Risk Taking)		Direct Effect (Entrepreneurial Orientation → Firm Performance)		Indirect Effect (Entrepreneurial Orientation → Innovation → Firm Performance)		Indirect Effect (Entrepreneurial Orientation → Risk Taking → Firm Performance)	
	Model 1	Model 2	Model 3	Model 4	Model 5	Model 6	Model 7	Model 8	Model 9	Model 10	Model 11	Model 12
Constant	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Age	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Gender	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Education	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Experience	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Firm Size	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Industry	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Entrepreneurial Orientation	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Innovation		[illegible]		[illegible]		[illegible]		[illegible]		[illegible]		[illegible]
Risk Taking		[illegible]		[illegible]		[illegible]		[illegible]		[illegible]		[illegible]
R^2	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Adjusted R^2	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
F-statistic	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Sobel Test									[illegible]	[illegible]	[illegible]	[illegible]
Bootstrap 95% CI									[illegible]	[illegible]	[illegible]	[illegible]

Note: [illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Table 7.0.0.1.0.0.0.1
Prevalence Rate Estimates of Dementia and Mild Cognitive Impairment (MCI) by Age and Gender Among Cognitively Healthy, 1990-2017

Age and Gender Groups	Year Estimate		Average Lifetime Risk (%)	Average Lifetime Risk (%)	Average Lifetime Risk (%)	Average Lifetime Risk (%)	Ratio of Lifetime Risk Estimates	Ratio of Lifetime Risk Estimates	Ratio of Lifetime Risk Estimates	Ratio of Lifetime Risk Estimates
	Dementia	MCI	Dementia	MCI	Dementia	MCI	Dementia	MCI	Dementia	MCI
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Table 7.0.0.0.0.0.0

Dysgeusia Mild Moderate Lymphocytes Lymphocytes Pancreas

Dry Dysgeusia Mouth Gastric Gastrectomy Cavity, 2010

Gastrectomy Gastric Gastrectomy	Gastrectomy Gastrectomy Gastrectomy	Gastrectomy Gastrectomy Gastrectomy	Average Gastrectomy Gastrectomy	Average Gastrectomy Gastrectomy	Average Gastrectomy Gastrectomy	Average Gastrectomy Gastrectomy	Mild Gastric Gastrectomy Gastrectomy	Gastrectomy Gastrectomy Gastrectomy	Gastrectomy Gastrectomy Gastrectomy
Gastrectomy Gastrectomy Gastrectomy	Gastrectomy Gastrectomy Gastrectomy	Gastrectomy Gastrectomy Gastrectomy	Gastrectomy Gastrectomy Gastrectomy	Gastrectomy Gastrectomy Gastrectomy	Gastrectomy Gastrectomy Gastrectomy	Gastrectomy Gastrectomy Gastrectomy	Gastrectomy Gastrectomy Gastrectomy	Gastrectomy Gastrectomy Gastrectomy	Gastrectomy Gastrectomy Gastrectomy

**Table 1.0.0.0

Table 1. Mean (SD) and Frequency (Percentage) of Variables

Stratified by Mild Cognitive Impairment (MCI) Status

Variable	Total Population (n = 1,000)		Cognitively Normal (n = 1,000)		Mild Cognitive Impairment (n = 1,000)		Standardized Mean Difference (SMD)	Mean Difference (95% CI)	Odds Ratio (95% CI)	Cohen's d (95% CI)
	Mean (SD)	Frequency (Percentage)	Mean (SD)	Frequency (Percentage)	Mean (SD)	Frequency (Percentage)				
Age (years)	72.4 (7.1)	—	71.8 (6.9)	—	73.0 (7.3)	—	0.172	1.2 (0.6, 1.8)	—	0.172 (0.086, 0.258)
Sex, male	—	512 (51.2%)	—	498 (49.8%)	—	526 (52.6%)	0.054	2.8 (−1.4, 7.0)	1.11 (0.94, 1.31)	—
Sex, female	—	488 (48.8%)	—	502 (50.2%)	—	474 (47.4%)				
Education (years)	12.6 (3.4)	—	13.1 (3.2)	—	12.1 (3.5)	—	0.298	−0.9 (−1.2, −0.6)	0.86 (0.79, 0.93)	−0.298 (−0.382, −0.214)
Hypertension	—	612 (61.2%)	—	580 (58.0%)	—	644 (64.4%)	0.132	6.4 (2.1, 10.7)	1.29 (1.08, 1.54)	—
Diabetes	—	184 (18.4%)	—	171 (17.1%)	—	197 (19.7%)	0.066	2.6 (−0.4, 5.6)	1.18 (0.95, 1.46)	—
Smoking, ever	—	401 (40.1%)	—	388 (38.8%)	—	414 (41.4%)	0.052	2.6 (−1.6, 6.8)	1.10 (0.92, 1.31)	—
Smoking, never	—	599 (59.9%)	—	612 (61.2%)	—	586 (58.6%)				
Baseline MMSE	27.3 (2.4)	—	28.1 (2.1)	—	26.5 (2.6)	—	0.664	−1.6 (−1.8, −1.4)	0.79 (0.74, 0.84)	−0.664 (−0.741, −0.587)
Baseline CDR-SB	1.4 (1.1)	—	1.0 (0.8)	—	1.8 (1.3)	—	0.545	0.8 (0.6, 0.9)	1.42 (1.31, 1.54)	0.545 (0.472, 0.618)
Baseline hippocampal volume (cm³)	6.8 (1.0)	—	7.2 (0.9)	—	6.4 (1.1)	—	0.421	−0.8 (−0.9, −0.7)	0.62 (0.57, 0.68)	−0.421 (−0.488, −0.354)
Baseline amyloid PET (SUVR)	1.18 (0.21)	—	1.09 (0.18)	—	1.27 (0.24)	—	0.389	0.18 (0.14, 0.22)	1.31 (1.24, 1.39)	0.389 (0.331, 0.447)

Note: Continuous variables are presented as mean (SD) and categorical variables as frequency (percentage). Standardized mean difference (SMD) is calculated using the pooled standard deviation. Odds ratios (OR) and Cohen's d are presented for illustrative comparisons only; no inferential tests are implied. Baseline MMSE and CDR-SB are measured at the first study visit. Hippocampal volume is adjusted for intracranial volume. Amyloid PET values are standardized uptake value ratios (SUVR). Sex, hypertension, diabetes, and smoking are coded as 1 = yes, 0 = no. Data are synthetic and do not correspond to any real cohort.

Received: 14 March 2026 | Revised: 22 May 2026 | Accepted: 9 June 2026 | Published online: 18 June 2026 | DOI: 10.5555/ecosmos.2026.0001

Dr. Ananda Sen, MD, PhD, Department of Neurology, Ashoka Medical College, Sector 14, Nandipur, Ashoka District, 411 204, India. ananda.sen@ashokamc.edu.in

Funding: This study was supported by the Ashoka Medical College Research Fund (Grant No. ARF-2024-07) and by a pilot grant from the Nandipur Neuroscience Institute. The funders had no role in study design, data collection, analysis, or the decision to publish.

© 2026 Ananda Sen, Rohini Menon, Kavita Joshi, Imtiaz Ahmed, Sunil Kumar Yadav, Tenzin Dolma, Aparna Bhattacharya, Vikram Singh Rathore, and Meenakshi Jolly. This work is licensed under Creative Commons Attribution 4.0 International. For commercial use, contact permissions@ecosmosjournal.com.

Table 1. [illegible]

Prevalence Rate Ratios of Dermatitis and Mortality of Parents by Occupational Group Controlling for Gender, 1994–[illegible]

Occupational Group (Reference Group: Farmers)	Sex Ratio		Average Age (Years)	Average Number of Children	Average Years of Education	Average Years Since Last Job	Ratio of Dermatitis Prevalence	Ratio of Mortality Prevalence	Ratio of Dermatitis Prevalence	Ratio of Mortality Prevalence
	Parents	Spouses	Parents	Parents	Parents	Parents	Parents	Parents	Spouses	Spouses
Farmers	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Fishers	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Hunters	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Loggers	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Miners	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Other	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Total	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Note: [illegible]

Sources: [illegible]

[illegible] Dermatitis Rating and Mortality Rate Variables Derived from Medical Records of Other Decedents. Cases with negative diagnostic codes are excluded from the [illegible] comparisons across the [illegible] Occupational Groups. Sex Ratio Variable Derived from Death Certificate Data.

[illegible] Occupational Classification. See [illegible] Occupational Classification.

[illegible] Dermatitis Prevalence Ratio Estimates Controlling for Sex, Age, Number of Children, Years of Education, and Years Since Last Job. Dermatitis Prevalence Ratio Estimates Controlling for Sex, Age, Number of Children, Years of Education, and Years Since Last Job. Mortality Prevalence Ratio Estimates Controlling for Sex, Age, Number of Children, Years of Education, and Years Since Last Job.

[illegible] Occupational Classification. See [illegible] Occupational Classification.

[illegible] Dermatitis Prevalence Ratio Estimates Controlling for Sex, Age, Number of Children, Years of Education, and Years Since Last Job. Mortality Prevalence Ratio Estimates Controlling for Sex, Age, Number of Children, Years of Education, and Years Since Last Job

Table 1. Kilo (2026)
Prevalence Rate Ratios of Dementia and Mild Cognitive Impairment (MCI) by Physical Activity Domain in Kumamoto, Japan, 2026

Independent Variable (Exposure)	Total Sample		Sex		Age Group		Marriage Status		Marriage Status		Marriage Status		Marriage Status		Marriage Status	
	Dementia	MCI	Dementia	MCI	Dementia	MCI	Dementia	MCI	Dementia	MCI	Dementia	MCI	Dementia	MCI	Dementia	MCI
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Table 1 ISO-2000
Prevalence Rate Statistics of Dermatitis and Mental Ill Patients
Ng Yong Kang Medical Centre (Kuantan, Malaysia), 2000–2011

Dermatitis Patients (Mental Illness Patients)	Year Statistics		Average Age (Years)	Average Length of Stay (Months)	Average Wait Time (Months)	Average Cost (Ringgit Per Year)	Male Patients (Mental Illness Patients)	Female Patients (Mental Illness Patients)	Average Cost (Ringgit Per Patient)
	Dermatitis	Mental Illness							
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Sources: [illegible] Medical Centre (2011)
[illegible]

[illegible]

[illegible]

Table 1. *Mediterranean Diet Adherence and Cardiometabolic Risk Factors by Physical Activity Status in Kirikkale, Türkiye, 2024–25*

Variable	Total Cohort		Inactive Stratum	Moderately Active Stratum	Strongly Active Stratum	Inactive vs Moderately Active	Inactive vs Strongly Active	Moderately Active vs Strongly Active	Trend across Activity Strata
	Mean (SD) / n (%)	Median [IQR] / n (%)	Mean (SD) / n (%)	Mean (SD) / n (%)	Mean (SD) / n (%)	Mean Difference [95% CI] / OR [95% CI]	Mean Difference [95% CI] / OR [95% CI]	Mean Difference [95% CI] / OR [95% CI]	Mean Difference [95% CI] / OR [95% CI]
Age, years	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Female sex	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Mediterranean Diet Adherence Score	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Physical Activity, MET-min/week	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Sitting time, hours/day	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Body mass index, kg/m²	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Waist circumference, cm	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Systolic blood pressure, mmHg	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Diastolic blood pressure, mmHg	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Fasting glucose, mg/dl	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Total cholesterol, mg/dl	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Triglycerides, mg/dl	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
HDL cholesterol, mg/dl	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
LDL cholesterol, mg/dl	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Hemoglobin A1c, %	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Hemoglobin, g/dl	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Hematocrit, %	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Platelet count, ×10³/µl	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Creatinine, mg/dl	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Uric acid, mg/dl	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Sodium, mmol/l	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Potassium, mmol/l	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Calcium, mg/dl	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Phosphorus, mg/dl	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Magnesium, mg/dl	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Ferritin, ng/ml	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Vitamin D, ng/ml	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Vitamin B12, pg/ml	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Folate, ng/ml	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Iron, µg/dl	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Total iron binding capacity, µg/dl	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Transferrin saturation, %	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Values are mean (SD) or median [IQR] for continuous variables and n (%) for categorical variables. Trend across activity strata was tested by linear regression for continuous variables and by Cochran–Armitage trend test for categorical variables. Mediterranean Diet Adherence Score: [illegible]. Physical Activity, MET-min/week: [illegible]. Sitting time: [illegible]. Body mass index: [illegible]. Waist circumference: [illegible]. Blood pressure: [illegible]. Fasting glucose: [illegible]. Total cholesterol: [illegible]. Triglycerides: [illegible]. HDL cholesterol: [illegible]. LDL cholesterol: [illegible]. Hemoglobin A1c: [illegible]. Hemoglobin: [illegible]. Hematocrit: [illegible]. Platelet count: [illegible]. Creatinine: [illegible]. Uric acid: [illegible]. Sodium: [illegible]. Potassium: [illegible]. Calcium: [illegible]. Phosphorus: [illegible]. Magnesium: [illegible]. Ferritin: [illegible]. Vitamin D: [illegible]. Vitamin B12: [illegible]. Folate: [illegible]. Iron: [illegible]. Total iron binding capacity: [illegible]. Transferrin saturation: [illegible].

Funding: [illegible]

Conflict of interest: [illegible]

Data availability: [illegible]

Ethical approval: [illegible]

Acknowledgments: [illegible]

Corresponding author: [illegible]

Author affiliations: [illegible]

**Table 7.0.0.0

Table 7.0.0.1.0.0.0.1

Propulsion Mind Mediator Lemonade and Mind of Thunder

Top Negative Mediator Lemonade Consumer, 2026

Consumer Brand Lemonade Consumer [illegible]	Top Negative Mediator Lemonade Consumer		Average Lemonade Consumer [illegible]	Average Lemonade Consumer [illegible]	Average Lemonade Consumer [illegible]	Average Lemonade Consumer [illegible]	Mind Lemonade Mediator Lemonade Consumer		Lemonade Mediator Lemonade Consumer		Lemonade Mediator Lemonade Consumer
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

Table 7.0.0.1.0.0.0.1

Regulatory Mind Mediation of Innovation and Brand Trust

**Sig. Regulatory Mind Mediation Between Innovation and Brand Trust, n = 300.0.0.0